dave297
30 Jun 2017
Randox stroke test milestone After all these years of hope & aspiration we long term investors have,at very very very long last,been rewarded by a milestone payment of £100k & I can hardly contain my excitement.It may lead to great things & my ,as yet unborn,grandchildren,may,one day benefit from my shrewd investment here,almost 20years ago !
The Potter
17 Jun 2017
Re: Ongoing move of mass spectrometry in... Well AR,It was only a suggestion!A 5% drop on Friday not changed your mind?Have a good weekend,
The Potter
14 Jun 2017
Re: Ongoing move of mass spectrometry in... AR,Well done. I see you are out of OXB with healthy profit.May I recommend PRM as your next buy?
Andy Reilly
02 Jun 2017
Re: Ongoing move of mass spectrometry in... TP - very fair summary - and lets hope luck works for you and PRM ultimately.
The Potter
02 Jun 2017
Re: Ongoing move of mass spectrometry in... Hi AR,Who knows what the future may bring. I have stayed with PRM, and recently averaged down at rock bottom, I hope!I was also able to profit from the spike in 2013.You have decided to go with OXB, where development of sales does not seem to be so much an issue, but debt is.Both OXB anb PRM are now penny shares, and react in penny share mode. It will be some time, if ever, before this trend is broken.So, patience is as important as luck, and both are definitely required in respect of these shares.
Andy Reilly
31 May 2017
Re: Ongoing move of mass spectrometry in... TP - I sold my entire holding of 30k PRM AT 26P ON 18/6/09..... and would be down £24,393 at current levels, so I do like the old principal of working for 'capital preservation' - it makes for sleeping well at night, and I do recommend it. ATB
Andy Reilly
31 May 2017
Re: Ongoing move of mass spectrometry in... Hi TP- well it has to be said that PRM hasnt done so well over recent times with Thermo F in such a dominant position, and it would certainly take some of the pain away IF they decided to pounce.... but I can understand why they are in no hurry...... for good reason I feel. Lets hope the good times can roll again soon for PRM, and Thermo dont pounce to take advantage of further weakness - unfortunately experience says that that is what tends to happen! Interesting to see what does eventually unfold, so I can but wish you lots of luck with this frustrating baby.. ATB, and thanks for your thoughts - ARPS - I have to say a lot of past comment about charts being irrelevant, BUT the little 3 year chart shows that when the 200 day EMA crossed UNDER the 50 day EMA it foretold of very bad times ahead for sentiment (and which continues!!), so its been a very useful tool to those who value it message, and which is why I take the chart very seriously.... It is THE voice of the markets,,,, and that is why I avoid 'belief at all cost!
The Potter
31 May 2017
Re: Ongoing move of mass spectrometry in... Hi AR,Your post is relevant, but I would attach no blame to Thermo F.They are offering PRM's product range, pursuant to the agreement, and obviously will do what is best for their own shareholders.I speculated some time ago that this agreement could have been partly responsible for PRM's missed targets that lead this BB to mistrust CP.However, were it not for the tie-up with Thermo F, PRM would be in a far sorrier state.I confess to having no idea of the proportion of the Thermo F sales to total sales, but would imagine that it is quite significant.As for buying PRM out, this would be ideal for all long-term holders But why would Thermo F even consider a buy out, when they already hold all the cards?
Andy Reilly
30 May 2017
Re: Ongoing move of mass spectrometry into t... TP_- I have to say that Thermo F dont seem to have PRM, or its shareholder's interests, at the top of their thoughtss, and seem only too happy to keep any benefits to themselves..... so it strikes me that the relationship with Thermo F seems more of a drag on PRM's SP than anything else... I must say I woudnt trust Thermo F IF I held PRM shares.... Maybe I have just got the wrong end of the stick with PRM (which is very possible!).... BUT I am not so sure there is very much comfort to be derived from the relationship with Thermo F. Perhaps you are able say what the benefits have been, AND how that has benefited PRM shareholders so far. The only benefit Thermo F would seem to bring to PRM, as far as I can see, would be their ability to buy PRM and its IP out, having not done a lot for PRM over the years.
The Potter
24 May 2017
Ongoing move of mass spectrometry into the clinic Cantor Fitzgerald Initiates Coverage on Thermo Fisher Scientific at OverweightMay 19, 2017| staff reporterNEW YORK (GenomeWeb) – Cantor Fitzgerald yesterday initiated coverage of Thermo Fisher Scientific with a rating of Overweight and a price target of $194 per share.In a note to investors, Cantor analyst Bryan Brokmeier said that as the largest company in the highly-fragmented life science tools and diagnostics sector, Thermo Fisher has "significant opportunity for organic growth at the expense of weaker competitors," adding that the company is "well-positioned to benefit from positive secular trends, as well as capture share given its position in attractive end markets."Brokmeier also noted that Thermo Fisher's largest end market, the biopharma industry, is growing at a mid- to high-single-digit rate and that the company's recent acquisition of pharma services firm Patheon should strengthen its offerings in this area.He further cited the ongoing move of mass spectrometry into the clinic as a potential driver of growth for the company. During its analyst meeting this week, Thermo Fisher revealed plans to launch an automated mass spec-based clinical analyzer next year.Thermo Fisher "is one of the best positioned companies to drive clinical mass spec adoption given their commercial reach and experience bringing clinical solutions to market," Brokmeier wrote.Cantor's note also highlighted Thermo Fisher's efforts to drive operating margins from the 22.5 percent posted in 2016 to between 25 percent and 26 percent in 2020. The target price is based the company trading at 19 times Cantor's 2018 adjusted cash earnings per share estimate.Thermo Fisher's shares were essentially flat at $171.78 during Friday morning trading on the New York Stock Exchange.
Andy Reilly
09 May 2017
Re: Nice! Mr F - Ah those pesky charts! Well what a little burst of self belief from you, and, it must be said, complete obscurity on your trading activity - I always find it interesting when a poster is 'less than clear'. I hope you do make 'loads of dose' (Ah the old Freudian slips!!!) with PRM, and only you know why you are being utterly obscure about your position, rather than being open with everybody.In my books its better to be open and clear, but if that doesnt suit you that of interest. Personally I remain reasonably upbeat about PRM, but as I explained, I didn't want to take on more risk, along with my OXB purchase (and which I posted on the appropriate BB - please note).Caution is a very useful quality, and you would gain more credibility if you opted to be open with your position in PRM, rather than trying to pass yourself off as a 'rather clever investor'. I hope your PRM purchase does make you lots of dosh, but come on, less posturing please!!! ATB
The Potter
09 May 2017
Re: Nice! Just to point out that PRM's broker (finncap) has a target price of 12p.
chutes
09 May 2017
Re: Nice! chart looks great if we break 8p, money to be had
Mr Frustration again
09 May 2017
Nice! Looks like I am going to make a shed load of dose on these (as I predicted I would when buying sub 5p) - good job I didn't listen to those pesky charts, LOL!
The Potter
09 May 2017
Re: Diggle buys again..... Hi AR,Thank you for those words of reassurance.
